Insmed makes ‘Arikayce’ that culture conversion trumps phase II primary endpoint miss
By Marie Powers
Wednesday, March 26, 2014
Early Wednesday, Insmed Corp. provided a detailed debriefing of data from the phase II trial of Arikayce (previously Arikace), its inhaled liposomal amikacin, to treat patients with resistant nontuberculous mycobacterial (NTM) lung infections.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.